About Oncotype DX Breast DCIS Score

Testing Core Biopsy Specimens

The COVID-19 pandemic has had a life-altering effect on the lives of the general population, but most notably health care providers and those with a diagnosis of cancer. We are all aware that in order to optimize provider, hospital, and clinic delivery of care, decisions are being made that are resulting in the postponement of both screening and diagnostic oncology services as well as elective surgery.

  • Our Oncotype DX® tests remain readily available and our laboratory continues to operate.
  • Core biopsies are the initial diagnostic procedure of choice for breast masses identified by physical exam or by imaging techniques.
  • The Oncotype DX test process was optimized to require only small amounts of tumor tissue and can be performed on a core biopsy of the breast cancer in lieu of the final resection specimen.

    • If you have any questions about the testing of a core biopsy specimen or general questions on Oncotype DX tests, you can continue to reach out to your local representative or medical science liaison (MSL) or call Customer Service at 866-ONCOTYPE (866-662-6897)


    Approximately 20% of all new breast cancers diagnosed in the United States are ductal carcinoma in situ (DCIS)1, but no two DCIS patients—or their tumors—are the same.

    20% of all new breast cancer in the US are DCIS
    It is estimated that by 2020, more than one million women in the United States will be living with a DCIS diagnosis, up from 500,000 in 20051

    The Oncotype DX Breast DCIS Score test is the first clinically-validated, commercially available genomic test for patients with DCIS. It looks at the unique biology of a patient’s tumor—so you can better personalize the treatment plan for each patient’s unique situation.

    FIND OUT IF MY PATIENT IS ELIGIBLE

    the first and only clinically-validated, commercially available genomic test for patients with DCIS

    An individualized assessment of risk

    Generally DCIS is a non-lethal form of breast cancer, but treatments—such as surgery, radiation therapy, and hormonal therapy—can be relatively aggressive. The key to choosing the right treatment options is assessing the patient’s risk for a local recurrence (DCIS or invasive carcinoma). Often, this assessment is based only on clinical and pathologic factors or nomograms (standardized guidelines that rely on population-based estimates of average risk).

    The Breast DCIS Score test provides an individualized assessment for the risk of local recurrence. Performed on a tumor sample after a biopsy or surgery, the test looks at 12 cancer-related genes in your patient’s tumor—giving you information that clinical and pathologic factors alone can’t provide. In fact, the test shows that patients with similar clinical and pathologic features do not necessarily have the same local recurrence risk.2-4

    The Breast DCIS Score test results include2-4:

    • An individualized prediction of the 10-year risk of any local recurrence (DCIS or invasive carcinoma) or an invasive local recurrence.
    • An established baseline for consideration of absolute benefit from radiation therapy (XRT).
    • Quantitative ER and PR single gene expression values.
    • A patient-friendly summary page to help explain the results to your patients
    EXAMPLE
    Case Study Comparison - Clinical use of the DCIS Score result
    63-year-old patient 66-year-old patient
    Menopausal Status: Postmenopausal
    Tumor Type: DCIS
    Tumor Size: 1.6 cm
    ER Status (IHC): Positive
    Nuclear Grade: 2
    Comedo Necrosis: Absent
    Margin Width: 2 mm     		Menopausal Status: Postmenopausal
    Tumor Type: DCIS
    Tumor Size: 1.0 cm
    ER Status (IHC): Positive
    Nuclear Grade: 2
    Comedo Necrosis: Absent
    Margin Width: 2 mm
    DCIS Score result:
    3
    		 DCIS Score result:
    57
    10% risk of any local recurrence (DCIS or invasive) 23% risk of any local recurrence (DCIS or invasive)
    3% risk of an invasive local recurrence 13% risk of an invasive local recurrence
    Cases submitted by Charles Leonard, MD, from Rocky Mountain Cancer Centers.

    Results your patients can relate to

    The Breast DCIS Score report includes the “DCIS Score result”, which is a number between 0-100.

    • Patients with a low risk estimate are likely to have a smaller absolute benefit from radiation therapy.
    • Patients with a high risk estimate are likely to have a greater absolute benefit from radiation therapy.

    This numeric score makes it easy for patients to understand their level of risk. As a result, discussing treatment options with your patients is easier and more efficient, and patients feel more confident about their decisions.

    Evidence it works

    Two validation studies—ECOG E5194 and the Ontario DCIS Cohort—confirm that the DCIS Score result predicts the 10-year risk of local recurrence.2-4 In addition, studies show that physicians regularly change treatment recommendations based on the test results.5,6


    LEARN MORE ABOUT CLINICAL EVIDENCE

    MORE TOPICS:

  • Clinical validation trials
  • Comparison to other genomic assays
  • Patient eligibility criteria
    • REFERENCES

    1. Allegra et al. J Natl Cancer Inst. 2010.
    2. Solin et al. J Natl Cancer Inst. 2013.
    3. Rakovitch et al. Breast Cancer Res Treat. 2015.
    4. Rakovitch et al. J Natl Cancer Inst. 2017.
    5. Alvarado et al. J Surg Oncol. 2015.
    6. Manders et al. Ann Surg Oncol. 2016.

    Stay in Touch

    Have questions? We're here to help.

     Contact Us
    Copyright © 2004- Genomic Health, Inc. All Rights Reserved.
    In the US and certain other jurisdictions, Genomic Health, Oncotype, Oncotype DX, Oncotype IQ, Oncotype MAP, Breast Recurrence Score, Recurrence Score, DCIS Score, Colon Recurrence Score, Genomic Prostate Score, GPS, AR-V7 Nucleus Detect, Pass It On: Until Every Woman Knows, and Making Cancer Care Smarter are trademarks of Genomic Health, Inc. Exact Sciences is a trademark of Exact Sciences Corporation.
    Making cancer care smarter.™